GALAPAGOS GENOMICS WKN: A0EAT9 ISIN: BE0003818359 Kürzel: GLPG Forum: Aktien Thema: Hauptdiskussion

Galapagos reports third quarter 2023 results and releases new encouraging data from CAR-T studies for presentation at ASH 2023 https://www.glpg.com/press-release/3916/galapagos-reports-third-quarter-2023-results-and-releases-new-encouraging-data-from-car-t-studies-for-presentation-at-ash-2023

Galapagos concludes strategic evaluation and signs letter of intent to transfer Jyseleca® business to Alfasigma https://www.glpg.com/press-release/3914/galapagos-concludes-strategic-evaluation-and-signs-letter-of-intent-to-transfer-jyseleca-business-to-alfasigma

Galapagos GAAP EPS of €0.43, revenue of €328.8M https://seekingalpha.com/news/3997161-galapagos-gaap-eps-of-043-revenue-of-3288m • Galapagos press release (NASDAQ:GLPG): 1H GAAP EPS of €0.43. • Revenue of €328.8M (+20.0% Y/Y).

Galapagos announces first half-year 2023 financial results https://www.glpg.com/press-release/3874/galapagos-announces-first-half-year-2023-financial-results

Galapagos GAAP EPS of €0.40, revenue of €178.9M https://seekingalpha.com/news/3965935-galapagos-gaap-eps-of-040-revenue-of-1789m • Galapagos press release (NASDAQ:GLPG): Q1 GAAP EPS of €0.40. • Revenue of €178.9M (+31.3% Y/Y). • Current financial investments and cash and cash equivalents totaled €3,990.1 million on 31 March 2023, as compared to €4,094.1 million on 31 December 2022. • We reiterate our full year 2023 cash burn guidance in the range of €380 and €420 million.

https://www.finanznachrichten.de/nachrichten-2023-05/58975776-galapagos-nv-galapagos-announces-departure-of-bart-filius-chief-operating-officer-and-chief-financial-officer-399.htm

diese Bewertung ist doch nur noch verrückt ... MK 2 ...Cash 4 Mrd. ..dazu die ganze Pipeline incl.Med was schon FCF generiert .. Verrückt Verrückter Galapagos

Galapagos to transfer drug discovery and research activities in France to NovAliX https://seekingalpha.com/news/3952944-galapagos-to-transfer-drug-discovery-and-research-activities-in-france-to-novalix • Belgian biotech Galapagos NV (NASDAQ:GLPG) on Thursday said it would transfer its drug discovery and research activities in Romainville, France to contract research organization NovAliX. • NovAliX will assume GLPG's research capabilities while GLPG will retain flexibility to access "necessary expertise and resources" through a five year-collaboration agreement, the company said in a statement. • The move by GLPG comes as part of its strategic reset announced in 2022. The deal is expected to close in July this year. • GLPG's employees in Romainville will also be transferred to NovAliX • The company said the financial impact of the deal is included in its previously announced 2023 cash burn guidance in the range of €380M to €420M.

https://www.glpg.com/press-release/3812/galapagos-and-novalix-enter-into-an-integrated-drug-discovery-collaboration

Oder ?

Also bekommst du das Unternehmen geschenkt … Das ist doch verrückt 😜

Roundabout 4 mrd.

Wieviel Nettocash haben sie noch ?

Galapagos reports FY 2022 results, sees further reduction of cash burn in FY 2023 https://seekingalpha.com/news/3940356-galapagos-reports-fy-2022-results-sees-further-reduction-of-cash-burn-in-fy-2023 • Galapagos press release (NASDAQ:GLPG): FY GAAP EPS of -€3.32 misses by €2.21. • Revenue of €505.3M (+4.2% Y/Y) misses by €77M. • For FY 2023, co anticipates further reduction of its cash burn and anticipates landing between €380 and €420 million (compared to €514 million for FY 2022). • Anticipates between €140 and €160 million net sales of Jyseleca for FY 2023.

Galapagos announces full year 2022 results and outlook for 2023 https://www.globenewswire.com/news-release/2023/02/23/2614774/0/en/Galapagos-announces-full-year-2022-results-and-outlook-for-2023.html

Jefferies Upgrades Galapagos to Hold, Lowers Price Target to $47.2 https://www.benzinga.com/news/23/01/30518170/jefferies-upgrades-galapagos-to-hold-lowers-price-target-to-47-2 Jefferies analyst Peter Welford upgrades Galapagos (NASDAQ:GLPG) from Underperform to Hold and lowers the price target from $49 to $47.2.